Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model

Anahita Rabiee, Yanhong Deng, Maria Ciarleglio, Jean L. Chan, Monica Pons, Joan Genesca, Guadalupe Garcia‐Tsao – 9 October 2022 – Clinically significant portal hypertension (CSPH), defined as hepatic venous pressure gradient (HVPG) ≥ 10 mm Hg, identifies patients with compensated cirrhosis at a high risk of decompensation. However, HVPG is an invasive and nuanced method.

Validation of novel point‐of‐care test for alanine aminotransferase measurement: A pilot cohort study

Jessica Howell, Huy Van, Minh Pham, Rohit Sawhney, Fan Li, Purnima Bhat, John Lubel, William Kemp, Stephen Bloom, Avik Majumdar, Geoff McCaughan, Samuel Hall, Timothy Spelman, Joseph S. Doyle, Margaret Hellard, Kumar Visvanathan, Alexander J. Thompson, Heidi E. Drummer, David Anderson – 9 October 2022

Complement complex 1 subunit q‐mediated hepatic stellate cell activation with connective tissue growth factor elevation is a prognostic factor for survival in rat and human chronic liver diseases

Akiko Eguchi, Motoh Iwasa, Ryosuke Sugimoto, Mina Tempaku, Kyoko Yoshikawa, Naohiko Yoshizawa, Davide Povero, Kazushi Sugimoto, Hiroshi Hasegawa, Yoshiyuki Takei, Hayato Nakagawa – 4 October 2022 – Complement complex 1 subunit q (C1q) has multiple functions, including cell migration, in addition to its traditional complement‐activating effect. Research shows C1q is a ligand for frizzled receptors (FZDs).

Deletion of adipocyte prohibitin 1 exacerbates high‐fat diet‐induced steatosis but not liver inflammation and fibrosis

Xiaolin Wang, Seung‐Jin Kim, Yukun Guan, Richard Parker, Robim M. Rodrigues, Dechun Feng, Shelly C. Lu, Bin Gao – 4 October 2022 – Adipose tissue dysfunction is closely associated with the development and progression of nonalcoholic fatty liver disease (NAFLD). Recent studies have implied an important role of prohibitin‐1 (PHB1) in adipose tissue function. In the current study, we aimed to explore the function of adipocyte PHB1 in the development and progression of NAFLD.

Glycine‐β‐muricholic acid antagonizes the intestinal farnesoid X receptor–ceramide axis and ameliorates NASH in mice

Jie Jiang, Yuandi Ma, Yameng Liu, Dasheng Lu, Xiaoxia Gao, Kristopher W. Krausz, Dhimant Desai, Shantu G. Amin, Andrew D. Patterson, Frank J. Gonzalez, Cen Xie – 4 October 2022 – Nonalcoholic steatohepatitis (NASH) is a rapidly developing pathology around the world, with limited treatment options available. Some farnesoid X receptor (FXR) agonists have been applied in clinical trials for NASH, but side effects such as pruritus and low‐density lipoprotein elevation have been reported. Intestinal FXR is recognized as a promising therapeutic target for metabolic diseases.

A higher FIB‐4 index is associated with an increased incidence of renal failure in the general population

Eva Maria Schleicher, Simon Johannes Gairing, Peter Robert Galle, Julia Weinmann‐Menke, Jörn M. Schattenberg, Karel Kostev, Christian Labenz – 3 October 2022 – The Fibrosis‐4 index (FIB‐4) is a recommended noninvasive fibrosis test in patients at risk of liver fibrosis. Chronic liver diseases are often associated with kidney diseases. This study aimed to investigate the association between FIB‐4 and the development of renal failure among the general population.

Zinc fingers and homeoboxes 2 is required for diethylnitrosamine‐induced liver tumor formation in C57BL/6 mice

Jieyun Jiang, Courtney Turpin, Guofang (Shirley) Qiu, Mei Xu, Eun Lee, Terry D. Hinds, Martha L. Peterson, Brett T. Spear – 3 October 2022 – Liver cancer, comprised primarily of hepatocellular carcinoma (HCC), is the third leading cause of cancer deaths worldwide and increasing in Western countries. We previously identified the transcription factor zinc fingers and homeoboxes 2 (Zhx2) as a regulator of hepatic gene expression, and many Zhx2 target genes are dysregulated in HCC. Here, we investigate HCC in Zhx2‐deficient mice using the diethylnitrosamine (DEN)–induced liver tumor model.

Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B

Man‐Fung Yuen, Elina Berliba, Wattana Sukeepaisarnjaroen, Sang Hoon Ahn, Tawesak Tanwandee, Young‐Suk Lim, Yoon Jun Kim, Kittiyod Poovorawan, Pisit Tangkijvanich, Christian Schwabe, Timothy Eley, Joanne Brown, Amy C. H. Lee, Emily P. Thi, Bhavna Paratala, Nagraj Mani, Michael J. Sofia, Gaston Picchio, Karen D. Sims, Edward J. Gane – 3 October 2022 – AB‐506 is a potent, pan‐genotypic small molecule capsid inhibitor that inhibits hepatitis B virus (HBV) pregenomic RNA encapsidation.

Subscribe to